Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Georgia: - Phoebe Putney Memorial Hospital — Albany, Georgia
- University Cancer and Blood Center LLC — Athens, Georgia
- Piedmont Hospital — Atlanta, Georgia
- Northside Hospital — Atlanta, Georgia
- Northside Hospital - Duluth — Duluth, Georgia
Phase 3 Recruiting Academic/Other
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in Georgia: - Grady Health System — Atlanta, Georgia
- Emory Proton Therapy Center — Atlanta, Georgia
- Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Georgia: - University Cancer & Blood Center, LLC — Athens, Georgia
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in Georgia: - Local Institution - 0326 — Atlanta, Georgia
- Northside Hospital — Atlanta, Georgia
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital — Marietta, Georgia
Phase 3 Recruiting Industry
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevaci…
Sponsor: Amgen
NCT ID: NCT06252649
Sites in Georgia: - Georgia Cancer Specialists — Atlanta, Georgia
Phase 2 Recruiting Industry
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newl…
Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in Georgia: - Piedmont Healthcare Inc. — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Georgia: - Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in Georgia: - Piedmont Healthcare — Atlanta, Georgia
Phase 2 Recruiting Industry
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line …
Sponsor: Oncolytics Biotech
NCT ID: NCT07446322
Sites in Georgia: - Emory Winship Cancer Institute — Atlanta, Georgia
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial studies the side effects and best dose of pidnarulex when given together with cemiplimab and to see how well it works in treating patients with microsatellite stable (MSS) colorectal cancer (CRC) that does not respond…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07147231
Sites in Georgia: - Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
Phase 2 Recruiting Academic/Other
This phase II trial studies how well giving zanidatamab before surgery (neoadjuvant) works in treating patients with colon and rectal cancer that is human epidermal growth factor receptor 2 positive (HER2+ve) who are planned for curative i…
Sponsor: Emory University
NCT ID: NCT07405476
Sites in Georgia: - Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
- Emory Decatur Hospital — Decatur, Georgia
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the met…
Sponsor: Chimeric Therapeutics
NCT ID: NCT06055439
Sites in Georgia: - Emory University — Atlanta, Georgia
Phase 1 Recruiting Industry
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT03715933
Sites in Georgia: - Emory University - Winship Cancer Institute — Atlanta, Georgia
Phase 1 Recruiting Industry
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participan…
Sponsor: Genentech, Inc.
NCT ID: NCT05581004
Sites in Georgia: - Winship Cancer Institute — Atlanta, Georgia
Phase 1 Recruiting Industry
Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the…
Sponsor: Astellas Pharma Inc
NCT ID: NCT07094204
Sites in Georgia: - Winship Cancer Institute at Emory University — Atlanta, Georgia
Phase 1 Recruiting Industry
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study …
Sponsor: Pliant Therapeutics, Inc.
NCT ID: NCT06270706
Sites in Georgia: - Winship Cancer Institute of Emory University — Atlanta, Georgia
Phase 1 Recruiting Industry
This study is open to adults with advanced cancer of the colon, rectum, stomach, or pancreas, that is the cancer cannot be removed by surgery or has spread. People can take part in this study if their previous treatment was not successful,…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06882746
Sites in Georgia: - Winship Cancer Institute — Atlanta, Georgia
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Georgia: - Northeast Georgia Medical Center Braselton — Braselton, Georgia
- Atlanta VA Medical Center — Decatur, Georgia
- Northeast Georgia Medical Center-Gainesville — Gainesville, Georgia
- The Longstreet Clinic - Gainesville — Gainesville, Georgia
- Low Country Cancer Care — Savannah, Georgia
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Georgia: - Northside Hospital — Atlanta, Georgia
- Northside Hospital - Duluth — Duluth, Georgia
- Liberty County Cancer Care — Hinesville, Georgia
- Regional Cancer Care - Jesup — Jesup, Georgia
- Northside Hospital - Gwinnett — Lawrenceville, Georgia
NA Recruiting Network
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in Georgia: - Lewis Cancer and Research Pavilion at Saint Joseph's/Candler — Savannah, Georgia
NA Recruiting Academic/Other
This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Georgia: - Northside Hospital — Atlanta, Georgia
- Tift Regional Medical Center — Tifton, Georgia
Recruiting Academic/Other
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is …
Sponsor: University of Rochester
NCT ID: NCT06073431
Sites in Georgia: - Northside Hospital — Atlanta, Georgia
- Northeast Georgia Medical Center Braselton — Braselton, Georgia
- John B Amos Cancer Center — Columbus, Georgia
- Northside Hospital - Duluth — Duluth, Georgia
- Northeast Georgia Medical Center-Gainesville — Gainesville, Georgia
Phase 4 Recruiting Industry
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory me…
Sponsor: Takeda
NCT ID: NCT06562543
Sites in Georgia: - Emory University — Atlanta, Georgia
Phase 4 Recruiting Academic/Other
The purpose of this research is to compare patient preferences for two bowel preparation options: low-volume tablets (Suflave/Sutab) versus the standard colon preparation using Golytely (polyethylene glycol). The study aims to enroll appro…
Sponsor: Morehouse School of Medicine
NCT ID: NCT07215000
Sites in Georgia: - Morehouse School of Medicine — Atlanta, Georgia
NA Recruiting Academic/Other
This clinical trial studies how well a web-based dyadic intervention works to manage psychoneurological symptoms for patients with colorectal cancer and their caregivers. Patients with colorectal cancer receiving chemotherapy experience se…
Sponsor: Emory University
NCT ID: NCT05663203
Sites in Georgia: - Emory University/Winship Cancer Institute — Atlanta, Georgia